Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. 2008

Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
Centre Antoine-Lacassagne, 33 Ave de Valombrose, 06189, Nice Cedex 2, France. eric.francois@cal.nice.fnclcc.fr

BACKGROUND The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer. METHODS Patients with metastatic colorectal cancer included in this study were aged at least 70 years, with a performance status of 0/1, without geriatric syndrome and without previous palliative chemotherapy. They received irinotecan [180 mg/m(2) intravenous (iv) infusion over 90 min] followed by folinic acid (400 mg/m(2) iv over 2 h), then 5FU (400 mg/m(2) iv bolus) and 5FU (2,400 mg/m(2) continuous iv infusion for 46 h) every 2 weeks. RESULTS Forty eligible patients were included. The median age was 77.3 years (range 70-84.7). The objective response rate was 40% and the stabilisation rate was 45%. Median progression-free survival was 8 months, overall survival was 17.2 months and cancer-related specific survival was 20.2 months. In total, 300 cycles of chemotherapy were administered with a median number of eight cycles per patient (range 1-18). Tolerance was good; grade 3/4 toxicities included diarrhoea (15%), asthenia (15%), nausea/vomiting (7.5%) and neutropenia (7.5%). One toxic death was observed due to grade 4 diarrhoea. CONCLUSIONS The FOLFIRI 1 regimen is a valid therapeutic option for elderly patients in good clinical condition.

UI MeSH Term Description Entries
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
July 2004, BMC cancer,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
January 2005, Oncology,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
January 2005, Oncology,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
January 2012, British journal of cancer,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
January 2007, Tumori,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
March 2006, British journal of cancer,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
April 2014, Anticancer research,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
September 2009, Cancer chemotherapy and pharmacology,
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
August 2022, Clinical oncology (Royal College of Radiologists (Great Britain)),
Eric François, and Jean-François Berdah, and Emmanuel Chamorey, and Gérard Lesbats, and Eric Teissier, and Jean-François Codoul, and Jean-Luc Badetti, and Christophe Hébert, and Véronique Mari
April 2009, BMC cancer,
Copied contents to your clipboard!